背景介绍 Blinatumomab is a biopharmaceutical drug used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It binds to CD19 on cancer cells (e.g. Raji cells) and CD3 on T cells simultaneously, thus bringing T lymphocytes closer to the cancer cells. The binding event potentiates unstimulated T cells and induces direct cytotoxicity against CD19+ cancer cells 产品介绍 Anti-CD19-Anti-CD3-His-Tag is a purified recombinant human bispecific T cell Engager (BiTE) based on Amgen's Blinatumomab. This BiTE has been tested for specific activity in both ELISA binding assay to CD19-biotin and functional reporter assays using Jurkat/NFAT-luc or Jurkat/IL2-Luc reporter cell lines in the presence of CD19+ Raji cells.